Goldman Sachs raised the firm’s price target on Viridian Therapeutics (VRDN) to $40 from $30 and keeps a Buy rating on the shares.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics: Promising Future with Strategic Trials and Financial Stability
- Viridian Therapeutics reports Q3 EPS (34c), consensus (94c)
- Viridian Therapeutics: Promising Future with Strategic Advancements and Financial Backing
- Viridian Therapeutics: Promising Prospects with Innovative TED Treatments and Financial Stability Justify Buy Rating
- Viridian Therapeutics submits BLA to the FDA for veligrotug